otilimab   Click here for help

GtoPdb Ligand ID: 11132

Synonyms: GSK-3196165 | GSK3196165 | MOR-103 | MOR103
Immunopharmacology Ligand
Compound class: Antibody
Comment: Otilimab (MOR103, GSK3196165) is a clinical stage fully human IgG1λ antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2). It is being investigated as a therapeutic for inflammatory diseases. MOR103 was developed using MorphoSys' HuCAL® technology, and has been fully out-licensed otilimab to GSK. MOR103 is claimed as MOR-04357 in patent WO2006122797A2 (by BLAST peptide sequence matching) [5].
No information available.
Summary of Clinical Use Click here for help
Otilimab was advanced into clinical trials, initially in rheumatoid arthritis and multiple sclerosis [3].

SARS-CoV-2 and COVID-19: Otilimab was investigated in a Phase 2 RCT, in patients with severe COVID-19, as a mechanism to reduce severe inflammatory lung complications, improve lung function and potentially improve clinical outcomes. However, in October 2021, GSK announced that this trial had failed to detect efficacy, and that development of otilimab for COVID-19 was being discontinued.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01023256 Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis Phase 1/Phase 2 Interventional MorphoSys AG 1
NCT01517282 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis Phase 1/Phase 2 Interventional MorphoSys AG 2
NCT03970837 Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) Phase 3 Interventional GlaxoSmithKline 2
NCT04333147 Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) Phase 3 Interventional GlaxoSmithKline
NCT02683785 A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis Phase 2 Interventional GlaxoSmithKline
NCT04376684 Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease Phase 2 Interventional GlaxoSmithKline